Bacterial Endocarditis - Causes, Treatment & When to See a Doctor

```html

What is Bacterial Endocarditis?

Bacterial endocarditis, also called infective endocarditis (IE), is a serious infection of the inner lining of the heart (the endocardium) and the heart valves. Bacteria enter the bloodstream, attach to damaged heart tissue, and multiply, forming clumps called vegetations. These vegetations can impair valve function, break off and travel to other organs, or cause systemic inflammation. The condition is relatively rare but carries a high risk of complications, including heart failure, stroke, and death if not treated promptly.

Most cases are caused by bacteria, but fungi or atypical organisms can also be responsible. The disease can develop suddenly (acute) or progress slowly over weeks to months (sub‑acute). Early recognition and treatment are essential for a good outcome.

Common Causes

While any bacteremia (bacteria in the blood) can potentially seed the heart, certain situations dramatically increase the risk. Below are the most frequent predisposing conditions and sources:

• Dental procedures – especially those that involve manipulating the gums or teeth without prophylactic antibiotics in high‑risk patients.
• Intravenous drug use (IVDU) – injecting contaminated substances introduces skin flora directly into the bloodstream.
• Prosthetic heart valves – artificial material is more susceptible to bacterial adhesion.
• Prior history of endocarditis – scar tissue provides a nidus for new infection.
• Congenital heart disease – structural abnormalities cause turbulent flow that damages endocardium.
• Recent cardiac surgery or catheterization – invasive procedures can introduce organisms.
• Chronic skin or soft‑tissue infections – such as cellulitis, abscesses, or infected ulcers.
• Urinary or gastrointestinal procedures – especially in patients with colon cancer or inflammatory bowel disease.
• Immunosuppression – patients on chemotherapy, steroids, or biologic agents have reduced ability to clear bacteria.
• Dental abscesses or poor oral hygiene – chronic oral infections can cause low‑grade bacteremia.

Associated Symptoms

Symptoms can be subtle early on but often include a combination of cardiac and systemic signs:

• Fever and chills (present in >90 % of cases)
• New or changing heart murmur
• Night sweats
• Fatigue, weakness, or unexplained weight loss
• Musculoskeletal pain (joint or muscle aches)
• Petechial rash, particularly on the palms and soles (Janeway lesions)
• Small, painless, red spots on the fingers or toes (Osler nodes)
• Blood‑tinged sputum or coughing up blood (if lung emboli occur)
• Neurologic symptoms such as confusion, focal weakness, or stroke‑like signs (from embolic events)
• Blood in the urine or flank pain (renal emboli or immune‑complex nephritis)

Because many of these signs overlap with common infections, maintaining a high index of suspicion—especially in people with the risk factors listed above—is crucial.

When to See a Doctor

Seek medical attention promptly if you experience any of the following:

• Fever >38 °C (100.4 °F) that persists for more than 48 hours, especially with a known heart valve problem.
• New heart murmur or a change in an existing murmur.
• Unexplained night sweats or significant weight loss.
• Painful or painless spots on the hands or feet (Osler nodes or Janeway lesions).
• Shortness of breath, chest pain, or sudden swelling of the legs.
• Neurologic changes: sudden weakness, speech difficulty, or vision loss.
• Persistent cough with blood‑streaked sputum.

If you fall into a high‑risk group (prosthetic valve, recent heart surgery, IV drug use, or known congenital heart disease), even milder symptoms warrant a prompt evaluation.

Diagnosis

Diagnosing bacterial endocarditis relies on a combination of clinical assessment, laboratory tests, and imaging. The major criteria are summarized in the modified Duke Criteria, widely used by cardiologists and infectious‑disease specialists.

1. Blood Cultures

• Three sets of aerobic and anaerobic cultures drawn from separate peripheral sites before antibiotics are started.
• Positive cultures for typical organisms (e.g., Staphylococcus aureus, Streptococcus viridans, Enterococcus) fulfill a major Duke criterion.

2. Echocardiography

• Trans‑thoracic echocardiogram (TTE) – non‑invasive, first‑line test; detects large vegetations.
• Trans‑esophageal echocardiogram (TEE) – more sensitive for small vegetations, prosthetic valves, or abscesses.

3. Laboratory Markers

• Elevated inflammatory markers: C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
• Complete blood count may show anemia of chronic disease or leukocytosis.
• Serum creatinine and urinalysis to assess kidney involvement.

4. Imaging for Complications

• CT or MRI of the brain for suspected embolic stroke.
• CT angiography of the chest/abdomen if there is suspicion of septic emboli to spleen, kidney, or lungs.

5. Additional Tests

• Serology for atypical agents (Coxiella, Bartonella, HACEK group) when cultures are negative.
• Polymerase chain reaction (PCR) on blood or excised tissue for fastidious organisms.

Treatment Options

Effective therapy combines prolonged intravenous (IV) antibiotics with supportive care. Surgery is indicated when medical therapy alone cannot control infection or when structural damage threatens heart function.

1. Antibiotic Therapy

• Empiric regimen (started after blood cultures are drawn) often includes vancomycin plus ceftriaxone or gentamicin, covering MRSA and gram‑negative organisms.
• Once the pathogen and sensitivities are known, therapy is narrowed—e.g., Streptococcus viridans → penicillin G or ceftriaxone + gentamicin for synergy.
• Duration: typically 4–6 weeks of IV antibiotics; shorter courses may be used for uncomplicated prosthetic‑valve infections with specific pathogens.
• Therapeutic drug monitoring (especially for vancomycin and aminoglycosides) is essential to avoid toxicity.

2. Surgical Intervention

• Indications include heart failure from severe valve dysfunction, uncontrolled infection despite antibiotics, large (>10 mm) vegetations with embolic risk, or development of an abscess, fistula, or prosthetic dehiscence.
• Procedures range from valve repair to valve replacement (mechanical or bioprosthetic).
• Post‑operative patients continue IV antibiotics for at least 2 weeks.

3. Supportive & Home Care

• Hospital admission for at least the initial 2–3 weeks of IV therapy, often through a peripherally inserted central catheter (PICC) or implanted port.
• Pain control, antipyretics, and hydration.
• Monitoring for drug side effects (renal function, hearing loss with aminoglycosides).
• Education on catheter care to prevent secondary line infections.

Prevention Tips

Because many cases stem from transient bacteremia, reducing opportunities for bacteria to enter the bloodstream is the cornerstone of prevention.

• Antibiotic prophylaxis before dental work for high‑risk patients (prosthetic valves, previous IE, certain congenital heart diseases) as recommended by the American Heart Association.<sup>1</sup>
• Maintain excellent oral hygiene: brush twice daily, floss, and schedule regular dental cleanings.
• Avoid non‑sterile tattoos, piercings, or body modifications without proper aseptic technique.
• For people who use intravenous drugs, access to harm‑reduction programs, sterile injection equipment, and addiction treatment dramatically lowers risk.
• Prompt treatment of skin infections, urinary tract infections, and respiratory infections.
• Regular follow‑up with a cardiologist for those with known valve disease or prosthetic devices.
• Vaccinations—especially influenza and pneumococcal vaccines—to reduce secondary infections that could seed the heart.

Emergency Warning Signs

---

Sources: Mayo Clinic. “Infective endocarditis.” 2023; American Heart Association. “Guidelines for the Prevention of Infective Endocarditis.” 2023; CDC. “Antibiotic Prophylaxis for Endocarditis.” 2022; National Institutes of Health. “Infective Endocarditis.” 2024; Cleveland Clinic. “Endocarditis – Symptoms & Treatment.” 2024; World Health Organization. “Antimicrobial Resistance.” 2023.

```